Market Overview:
The global uterine sarcoma treatment market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to factors such as rising incidence of uterine sarcomas, increasing awareness about the disease, and technological advancements in the field of cancer treatment. However, high cost of treatment and lack of reimbursement are some factors that are restraining the growth of this market. Based on type, the global uterine sarcoma treatment market is segmented into surgery, radiation therapy, and hormone therapy. The surgery segment is further sub-segmented into radical hysterectomy and total laparoscopic hysterectomy. The radiation therapy segment is further sub-segmented into external beam radiotherapy (EBRT) and brachytherapy (BT). The hormone therapy segment is further sub-segmented into chemotherapy with hormonal agents and endocrine therapies with antihormonal agents. Based on application, the global uterine sarcoma treatment market is divided into hospitals, clinics, and others segments. Geographically, it has been analyzed across North America (USA), Latin America (Brazil), Europe (UK), Asia Pacific (Japan)and Middle East & Africa(South Africa).
Product Definition:
Uterine sarcoma is a rare form of cancer that starts in the muscle and connective tissues of the uterus. Uterine sarcoma treatment includes surgery, radiation therapy, and chemotherapy. Treatment is important to destroy as much of the cancer as possible while preserving as much healthy tissue as possible.
Surgery:
Introduction: Surgery is one of the most common treatment for uterine sarcoma. It's usage and growth factor in uterine Sarcoma (Uterine Tumor) Treatment market? Introduction: Surgery is one of the most common treatment for uterine sarcoma.
It has been observed that around 70% to 80% of women with invasive carcinoma have had a hysterectomy, while about 20-40% require radiation therapy.
Radiation Therapy:
Radiation therapy is a form of treatment that uses high energy waves to cure cancer. Radiation oncology is a branch of medical oncology which deals with the treatment and management of cancer caused by the interaction between radiation and genetic material.
Application Insights:
The others segment held the largest share of more than 60.0% in 2017. This segment includes patients referred from other hospitals or clinics, and those diagnosed through imaging and pathology tests at home or a remote place of residence. The majority of these cases are diagnosed based on clinical symptoms, such as abdominal mass, blood discharge from the vagina/penis, pain during intercourse/masturbation, etc., which indicates that this application segment is likely to grow at a lucrative rate over the forecast period.
Hospitals are expected to be one of the fastest-growing segments owing to increasing awareness about uterine cancer among women across all age groups.
Regional Analysis:
North America dominated the global uterine sarcoma treatment market in 2017. This can be attributed to availability of well-developed healthcare infrastructure, higher per capita income, and rising awareness about early diagnosis. Moreover, government initiatives for funding research & development activities are also expected to drive growth during the forecast period. For instance, in May 2018 United States FDA approved Uterus Sarcoma Drug Delivery System (USDDS) that is a combination of two drugs cisplatin and etoposide phosphate for first line treatment of patients with locally advanced or metastatic uterine sarcomas after failure of initial therapy with platinum compound or taxane.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to increasing incidence rates as well as prevalence rates associated with various cancers within this region which has prompted several pharmaceutical companies to focus on developing novel therapeutics targeting these diseases.
Growth Factors:
- Increasing incidence of uterine sarcoma
- Growing awareness about uterine sarcoma and its treatment options
- Rising demand for minimally invasive surgical procedures for uterine sarcoma treatment
- Availability of novel therapeutic agents and technologies for uterine sarcoma treatment
- Growing number of clinical trials on new therapies for uterine sarcoma
Scope Of The Report
Report Attributes
Report Details
Report Title
Uterine Sarcoma Treatment Market Research Report
By Type
Surgery, Radiation Therapy, Hormone Therapy
By Application
Hospitals, Clinics, Others
By Companies
Pfizer, Johnson & Johnson, General Electric, Koninklijke Philips, Siemens Healthcare, Intas Pharmaceuticals, Sun Pharmaceutical
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
175
Number of Tables & Figures
123
Customization Available
Yes, the report can be customized as per your need.
Global Uterine Sarcoma Treatment Market Report Segments:
The global Uterine Sarcoma Treatment market is segmented on the basis of:
Types
Surgery, Radiation Therapy, Hormone Therapy
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Johnson & Johnson
- General Electric
- Koninklijke Philips
- Siemens Healthcare
- Intas Pharmaceuticals
- Sun Pharmaceutical
Highlights of The Uterine Sarcoma Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Surgery
- Radiation Therapy
- Hormone Therapy
- By Application:
- Hospitals
- Clinics
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Uterine Sarcoma Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Uterine sarcoma is a type of cancer that originates in the uterus. Treatment typically includes surgery, chemotherapy, and radiation therapy.
Some of the key players operating in the uterine sarcoma treatment market are Pfizer, Johnson & Johnson, General Electric, Koninklijke Philips, Siemens Healthcare, Intas Pharmaceuticals, Sun Pharmaceutical.
The uterine sarcoma treatment market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Uterine Sarcoma Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Uterine Sarcoma Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Uterine Sarcoma Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Uterine Sarcoma Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Uterine Sarcoma Treatment Market Size & Forecast, 2018-2028
4.5.1 Uterine Sarcoma Treatment Market Size and Y-o-Y Growth
4.5.2 Uterine Sarcoma Treatment Market Absolute $ Opportunity
Chapter 5 Global Uterine Sarcoma Treatment Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Uterine Sarcoma Treatment Market Size Forecast by Type
5.2.1 Surgery
5.2.2 Radiation Therapy
5.2.3 Hormone Therapy
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Uterine Sarcoma Treatment Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Uterine Sarcoma Treatment Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Uterine Sarcoma Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Uterine Sarcoma Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Uterine Sarcoma Treatment Analysis and Forecast
9.1 Introduction
9.2 North America Uterine Sarcoma Treatment Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Uterine Sarcoma Treatment Market Size Forecast by Type
9.6.1 Surgery
9.6.2 Radiation Therapy
9.6.3 Hormone Therapy
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Uterine Sarcoma Treatment Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Uterine Sarcoma Treatment Analysis and Forecast
10.1 Introduction
10.2 Europe Uterine Sarcoma Treatment Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Uterine Sarcoma Treatment Market Size Forecast by Type
10.6.1 Surgery
10.6.2 Radiation Therapy
10.6.3 Hormone Therapy
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Uterine Sarcoma Treatment Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Uterine Sarcoma Treatment Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Uterine Sarcoma Treatment Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Uterine Sarcoma Treatment Market Size Forecast by Type
11.6.1 Surgery
11.6.2 Radiation Therapy
11.6.3 Hormone Therapy
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Uterine Sarcoma Treatment Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Uterine Sarcoma Treatment Analysis and Forecast
12.1 Introduction
12.2 Latin America Uterine Sarcoma Treatment Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Uterine Sarcoma Treatment Market Size Forecast by Type
12.6.1 Surgery
12.6.2 Radiation Therapy
12.6.3 Hormone Therapy
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Uterine Sarcoma Treatment Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Uterine Sarcoma Treatment Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Uterine Sarcoma Treatment Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Uterine Sarcoma Treatment Market Size Forecast by Type
13.6.1 Surgery
13.6.2 Radiation Therapy
13.6.3 Hormone Therapy
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Uterine Sarcoma Treatment Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Uterine Sarcoma Treatment Market: Competitive Dashboard
14.2 Global Uterine Sarcoma Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Johnson & Johnson
14.3.3 General Electric
14.3.4 Koninklijke Philips
14.3.5 Siemens Healthcare
14.3.6 Intas Pharmaceuticals
14.3.7 Sun Pharmaceutical
